Abbott schedules October 21 results for Abbott Laboratories stock

Published on 10/19/2026 at 09:27 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Abbott expects USD 1.42 per share on October 21. Abbott Laboratories stock costs EUR 93.45 on October 19, 2026, 0.64 percent above EUR 92.86.

Earnings and valuation markers

Abbott expects USD 1.42 per share for the October 21, 2026 report.
Second-quarter revenue reached USD 12.59 billion, up 13.00 percent year over year.
Abbott Laboratories stock trades at EUR 93.45 at 9:22 a.m. CEST at Lang & Schwarz on October 19, 2026, 0.64 percent above the Xetra close of October 16, 2026.
Rothschild & Co Redburn raised its target from USD 119.00 to USD 127.00 on October 2, 2026.

Pharma-Campus Architektur-Render Abbott Laboratories US0028241000 Illinois — Abbott Laboratories US0028241000 Architektur-Render moderner Pharma-Campus mit Glas-Stahl-Gebäuden Grünanlagen und Teich Illinois, Illustration mit AI erstellt.

Abbott Laboratories (ISIN US0028241000) was trading at EUR 93.45 at Lang & Schwarz on October 19, 2026, at 9:22 a.m. CEST, 0.64 percent above the Xetra close of October 16, 2026 at EUR 92.86. The company is scheduled to report third-quarter results before the market opens on October 21, 2026, with analysts expecting USD 1.42 in earnings per share and USD 12.99 billion in revenue, according to Zolmax.

October 21 is the next test

The estimate sets a clear benchmark for Abbott's next report. The projected USD 12.99 billion revenue would exceed the USD 11.37 billion reported for the same quarter a year earlier, while expected earnings per share of USD 1.42 compares with USD 1.30, according to MarketBeat. The figures make revenue execution and the earnings outlook the main tests for the medical-products group.

What does the estimate imply?

Abbott's second-quarter report provides the latest operating comparison. Revenue was USD 12.59 billion, up 13.00 percent year over year, and adjusted earnings per share of USD 1.31 exceeded the USD 1.28 consensus by USD 0.03, according to Zolmax. That prior quarter gives investors a recent reference point for judging whether the October report extends the growth pace.

Three dates and target changes

On October 2, 2026, Rothschild & Co Redburn raised its target from USD 119.00 to USD 127.00 and upgraded Abbott from neutral to buy, according to Zolmax. On October 7, 2026, Barclays began coverage with an overweight rating and a USD 120.00 target, the same report said. On October 21, 2026, Abbott is expected to publish third-quarter results before the market opens, followed by a conference call at 9:00 a.m. ET.

Upcoming reporting date

The next substantiated company date is October 21, 2026, for the third-quarter earnings release and the 9:00 a.m. ET conference call. The scheduled report gives the recent analyst targets a near-term operating checkpoint rather than a standalone valuation signal.

Stock trades modestly above Xetra close

Abbott Laboratories was trading at EUR 93.45 at Lang & Schwarz on October 19, 2026, at 9:22 a.m. CEST, up 0.64 percent versus the Xetra close of October 16, 2026 at EUR 92.86. Its primary listing is on the NYSE, where the company is known for medical devices, diagnostics, nutrition and established pharmaceuticals.

The further course of trading is shown by the continuously updated real-time quote of Abbott Laboratories stock.